ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1395

Prevalence and Significance of MEFV GENE Mutations in Patients with Sarcoidosis

Senol Kobak1, Fidan Sever2, Ozlem Goksel3, Tuncay Goksel3, Mehmet Orman4 and Afig Berdeli5, 1Rheumatology, Sifa University Faculty of Medicine, 35100, Turkey, 2Chest Disease, Sifa University, Izmir, Turkey, 3Chest Disease, Ege University, Izmir, Turkey, 4Ege University Department of Statistic, Associated Professor, Izmir, Turkey, 5Genetics and Molecular Medicine, Ege University, Izmir, Turkey

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: sarcoidosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster Session II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Sarcoidosis is a chronic granulomatous disease. Pyrin, is encoded by the MEFV gene and has anti-inflammatory effects in the inflammasoma regulation. MEFV gene mutations affects the  inflammatory cascade and cause familial Mediterranean fever. The relationship between different rheumatic diseases and MEFV gene mutations are shown in previous studies. Aim:The aim of this study was to determine the MEFV gene prevalence in Turkish patients with sarcoidosis and to determine the possible correlation between the occurrence of mutations and disease phenotype.

Methods: Seventy-eight sarcoidosis patients and age, gender and ethnicity compatible 85 healthy controls were included in the study. The most common eight MEFV gene mutations were investigated by PCR method. 

Results: Among seventy-eight sarcoidosis patients MEFV gene mutation was detected in nine patients(%11.5). The distribution of the nine mutations; three (3.8%) V726A, two (2.5%) E148Q, two (2.5%) M680, a (1.3%) A744S, one (1.3%) of K695, respectively. None of the  sarcoidosis patients were M694V, M694I, R761H and P369S and compound heterozygous carriers (Table 1). MEFV gene mutations frequency in the healthy control group was found to be 22.4%.The distribution of  MEFV gene mutations in the healthy control were; E148Q 9 (10.6%), M694V 2 (2.3%), M694I 1 (1.2%), M680 1 (1.2%), V726A 2 (2.3%), A744S1 (1.2%), K695 2 (2.3%), P369S1 (1.2%), respectively, Compared with the control group, a lower carrier frequency of MEFV gene mutations were detected in patients with sarcoidosis, but it was not statistically significant(p=0.067). In the sarcoidosis group, while serum ESR and CRP levels were  significantly higher in the mutation carrier group than those of the non-carrier group (p=0.01,p=0.04). In the sarcoidosis group, while arthritis,enthesitis and ankle arthritis  were  significantly more frequent in the mutation carrier group than those of the non-carrier group (p=0.028, p=0.05, p=0.05 respectively). 

Conclusion:

In Turkish patients with sarcoidosis, we found a lower frequency of MEFV gene mutations compared with healthy control group. Sarcoidosis mutation carrier group were found to be associated with high serum acute phase response , arthritis and enthesitis. The presence of MEFV gene mutation may have a protective role for the development of sarcoidosis. Prospective studies with large patient series are need on this subject.


Disclosure: S. Kobak, None; F. Sever, None; O. Goksel, None; T. Goksel, None; M. Orman, None; A. Berdeli, None.

To cite this abstract in AMA style:

Kobak S, Sever F, Goksel O, Goksel T, Orman M, Berdeli A. Prevalence and Significance of MEFV GENE Mutations in Patients with Sarcoidosis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/prevalence-and-significance-of-mefv-gene-mutations-in-patients-with-sarcoidosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-and-significance-of-mefv-gene-mutations-in-patients-with-sarcoidosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology